Neoadjuvant pyrotinib plus trastuzumab, and chemoterapy in patients with HER2-positive early breast cancer: a real-world study

被引：0
|
作者：
Zhou, Jun
Wang, Rui
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-01-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-01-05
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Liu, Lu
    Zhu, Mingzhi
    Wang, Yanyan
    Li, Muhan
    Gu, Yuanting
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [2] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
    Lu Liu
    Mingzhi Zhu
    Yanyan Wang
    Muhan Li
    Yuanting Gu
    [J]. World Journal of Surgical Oncology, 21
  • [3] Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study
    Li, Qi
    Wang, Yanyan
    Zhu, Mingzhi
    Gu, Yuanting
    Tang, Yajing
    [J]. GLAND SURGERY, 2021, 10 (12) : 3389 - 3402
  • [4] Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer
    Ma, Xiangmin
    Zhang, Xiangmei
    Zhou, Xinping
    Ren, Xiaofei
    Ma, Xindi
    Zhang, Weifang
    Yang, Ruiling
    Song, Tao
    Liu, Yunjiang
    [J]. MEDICINE, 2022, 101 (40) : E30892
  • [5] Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study
    Zhang, Qiongwen
    He, Ping
    Tian, Tinglun
    Yan, Xi
    Huang, Juan
    Zhang, Zhang
    Zheng, Hong
    Zhong, Xiaorong
    Luo, Ting
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [6] Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
    Hall, Benjamin James
    Bhojwani, Ajay Ashok
    Wong, Helen
    Law, Andrea
    Flint, Helen
    Ahmed, Eliyaz
    Innes, Helen
    Cliff, Joanne
    Malik, Zaf
    O'Hagan, Julie Elizabeth
    Hall, Allison
    Sripadam, Rajaram
    Tolan, Shaun
    Ali, Zulfiqar
    Hart, Clare
    Errington, Douglas
    Alam, Farida
    Giuliani, Rosa
    Mehta, Shaveta
    Khanduri, Sheena
    Thorp, Nicky
    Jackson, Richard
    Cicconi, Silvia
    Palmieri, Carlo
    [J]. BREAST JOURNAL, 2022, 2022
  • [7] Trastuzumab (HLX02) plus Pertuzumab as Dualtarget Neoadjuvant Therapy for HER2-positive Breast Cancer: A Real-World Study
    Liu, Yin
    Zuo, Wen-Jia
    Wang, Ruo-Xi
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    [J]. CANCER RESEARCH, 2023, 83 (05)
  • [8] Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
    Li, Feng
    Xu, Fengrui
    Li, Jianbin
    Wang, Tao
    Bian, Li
    Zhang, Shaohua
    Jiang, Zefei
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (02)
  • [9] The efficacy and safety of epirubicin and cyclophosphamide combined with pyrotinib in neoadjuvant treatment for HER2-positive breast cancer: A real-world study
    Li, Fu
    Liang, Yimin
    Luo, Ming
    Shen, Jiayue
    Zhou, Taosheng
    Liang, Yajing
    Tang, Xiaoqi
    Yuan, Huiming
    Zeng, Jian
    [J]. FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
    Wang, B.
    You, S.
    Xie, Y.
    Xu, F.
    Sang, D.
    Luo, T.
    Yuan, P.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S361 - S362
12345